摘要
目的:研究病理明确诊断的小细胞肺癌采用自体外周血干细胞移植支持下的高剂量化疗的疗效。方法:6例患者选自常规化疗达到CR、PR或手术切除原发灶的小细胞肺癌对其采用自体外周血干细胞移植支持下的高剂量环磷酰胺CTX、足叶乙甙VP-16、卡铂CBP的化疗CTX 6 000mg/m2VP-16 1 200mg/m2CBP 1 200mg/m2其中5例进行了化疗后的局部放疗并进行了长期随访,中位随诊时间为26.516~33个月。结果:除1例小细胞肺癌死于高剂量化疗后27个月余全部生存。最常见的毒副反应为恶心呕吐和粒细胞缺乏性发热未发现移植后的骨髓功能不全及其他严重并发症移植后3个月内的相关死亡率为零。结论:此方法对小细胞肺癌的治疗结果令人满意且较安全值得扩大病例数进一步研究。
Objective To study the efficacy of high-dose chemotherapy supported by autologous peripheral blood progenitor cell transplantation APBPCT in the treatment of small cell lung cancer SCLC. Method and Materials Six patients with pathologically confirmed SCLC being reached CRPR after conventional chemotherapy or surgically removed primary lesion have received high-dose chemotherapy which included Cyclophosphamide 6 000mg/m2 Etoposide 1 200mg/m2 Carboplatin 1 200mg/m2 following APBPCT 5 of 6 patients also received local radiotherapy after the procedure all of them had been consecutively followed-up and median follow-up time was 26.516/33 months. Results Five patients were still alive but one died of recurred cancer within 27 months after high-dose chemotherapy. The most common side effects were gastrointestinal disturbance and neutropenic febrile. No bone marrow dysfunction and other severe complications were found. The related mortality in three months was none. Conclusion The results of high-dose chemotherapy with APBPCT in the treatment of SCLC were encouraged and it is also safe. Further research with extended cases is not just worthwhile but also mandatory.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2000年第10期753-756,共4页
Chinese Journal of Clinical Oncology
关键词
小细胞肺癌
自体外周血干细胞移植
高剂量化疗
Small cell lung cancer High-dose chemotherapy Autologous peripheral blood progenitor cell trans-plantation